Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas

Journal of Neuro-Oncology

Volumn 110, Issue 2, 2012, Pages 279-285

  Holdhoff, Matthias ^a,b   Ye, Xiaobu ^a   Blakeley, Jaishri O ^a   Blair, Lindsay ^a   Burger, Peter C ^a   Grossman, Stuart A ^a   Diaz Jr , Luis A ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Glioblastoma; MGMT promoter methylation; Molecular biomarker; Personalized medicine; Prognostic biomarker

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL DECISION MAKING; CROSS-SECTIONAL STUDY; DNA METHYLATION; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GLIOBLASTOMA; HUMAN; MOLECULAR DIAGNOSIS; ONLINE SYSTEM; PATIENT CARE; PREDICTION; PROGNOSIS; PROMOTER REGION; QUESTIONNAIRE;

ADULT; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DECISION MAKING; DELIVERY OF HEALTH CARE; GLIOBLASTOMA; HUMANS; INDIVIDUALIZED MEDICINE; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84867856045     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0968-3     Document Type: Article

References (14)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5 year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466. doi: 10.1016/S1470-2045(09)70025-7
2. Holdhoff M, Grossman SA (2011) Controversies in the adjuvant therapy of high-grade gliomas. Oncologist 16:351-358
3. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812. doi: 10.1126/science.1164382
4. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773. doi: 10.1056/NEJMoa0808710
5. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003. doi: 10.1056/NEJMoa043331
6. Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512-3518. doi: 10.1002/cncr.24406
7. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
8. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189-4199. doi: 10.1200/JCO.2007.11.5964
9. van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276-1284. doi: 10.1002/cncr.11187
10. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024. doi: 10.1056/NEJMoa051918
11. Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, Buchdunger E, Black PM, Stiles CD (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60:5143-5150
12. Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA et al (2005) Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 34:181-185. doi: 10.1016/j.bcmd.2004.11.006
13. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K et al (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: north American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12:4899-4907. doi: 10.1158/1078-0432.CCR-06-0773
14. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE et al (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23:9359-9368. doi: 10.1200/JCO.2005.03. 2185